Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Alzheimer's drug slows functional decline

Use of tarenflurbil in patients with mild Alzheimer's disease appears to slow decline in functional ability compared with placebo, a UK phase II trial shows.

In patients with mild disease taking 800mg of tarenflurbil twice a day, there was a 46% lower rate of decline on the activities of daily living scale and a 36% lower rate of decline in global function, compared with placebo.

But there was no benefit of tarenflurbil at either 400mg or 800mg in patients with moderate Alzheimer's disease.

Lancet Neurology 2008; 30 April early online publication

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say